Emergent BioSolutions (EBS) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 66.2% versus a loss of 28.7%. Over five years, TKNO leads with a -62.3% price change compared with -86.1% for EBS. Alpha Teknova is the larger company by market cap ($467.6 million vs $362.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | TKNO |
|---|---|---|
| Share price | $7.07 | $8.71 |
| Market cap | $362.50M | $467.62M |
| 1-day change | +1.73% | -0.46% |
| YTD return | -42.80% | +129.21% |
| 1-year return | -28.73% | +66.22% |
| 5-year return | -86.05% | -62.29% |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.46 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $9.48 |
| 52-week low | $4.36 | $1.91 |
| Distance from 52-week high | -49.72% | -8.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.59% | +3.33% |
| Average volume | 1.16M | 230.41K |
| Shares outstanding | 51.27M | 53.69M |
| Employees | 900 | 158 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TKNO has outperformed EBS by 95.0 percentage points over the past year.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Healthcare · Drug Manufacturers - Specialty & Generic · 900 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 158 employees
EBS vs TKNO FAQ
Which is bigger, Emergent BioSolutions or Alpha Teknova?
Alpha Teknova (TKNO) is larger, with a market capitalization of $467.62M compared with $362.50M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or TKNO?
TKNO returned +66.22% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Alpha Teknova in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.